127 related articles for article (PubMed ID: 20653334)
1. Mipomersen.
Am J Cardiovasc Drugs; 2010; 10(4):271-9. PubMed ID: 20653334
[TBL] [Abstract][Full Text] [Related]
2. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
Bell DA; Hooper AJ; Burnett JR
Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
[TBL] [Abstract][Full Text] [Related]
3. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.
Ricotta DN; Frishman W
Cardiol Rev; 2012; 20(2):90-5. PubMed ID: 22293857
[TBL] [Abstract][Full Text] [Related]
4. Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia.
Haddley K
Drugs Today (Barc); 2011 Dec; 47(12):891-901. PubMed ID: 22348914
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
6. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
[TBL] [Abstract][Full Text] [Related]
7. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?
Ito MK
Ann Pharmacother; 2007 Oct; 41(10):1669-78. PubMed ID: 17848425
[TBL] [Abstract][Full Text] [Related]
8. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.
Burnett JR
Curr Opin Mol Ther; 2006 Oct; 8(5):461-7. PubMed ID: 17078389
[TBL] [Abstract][Full Text] [Related]
9. Mipomersen as a potential adjunctive therapy for hypercholesterolemia.
Patel N; Hegele RA
Expert Opin Pharmacother; 2010 Oct; 11(15):2569-72. PubMed ID: 20707601
[TBL] [Abstract][Full Text] [Related]
10. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
[TBL] [Abstract][Full Text] [Related]
11. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
Santos RD; Raal FJ; Catapano AL; Witztum JL; Steinhagen-Thiessen E; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):689-99. PubMed ID: 25614280
[TBL] [Abstract][Full Text] [Related]
12. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia.
Santos RD; Raal FJ; Donovan JM; Cromwell WC
J Clin Lipidol; 2015; 9(2):201-9. PubMed ID: 25911076
[TBL] [Abstract][Full Text] [Related]
13. Mipomersen sodium: first global approval.
Hair P; Cameron F; McKeage K
Drugs; 2013 Apr; 73(5):487-93. PubMed ID: 23564617
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein B synthesis inhibition: results from clinical trials.
Visser ME; Kastelein JJ; Stroes ES
Curr Opin Lipidol; 2010 Aug; 21(4):319-23. PubMed ID: 20508521
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein B antisense inhibition--update on mipomersen.
Gebhard C; Huard G; Kritikou EA; Tardif JC
Curr Pharm Des; 2013; 19(17):3132-42. PubMed ID: 23317401
[TBL] [Abstract][Full Text] [Related]
16. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.
Agarwala A; Jones P; Nambi V
Curr Atheroscler Rep; 2015 Jan; 17(1):467. PubMed ID: 25398643
[TBL] [Abstract][Full Text] [Related]
17. Is mipomersen ready for clinical implementation? A transatlantic dilemma.
Sjouke B; Balak DM; Beuers U; Ratziu V; Stroes ES
Curr Opin Lipidol; 2013 Aug; 24(4):301-6. PubMed ID: 23759796
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.
Akdim F; Stroes ES; Sijbrands EJ; Tribble DL; Trip MD; Jukema JW; Flaim JD; Su J; Yu R; Baker BF; Wedel MK; Kastelein JJ
J Am Coll Cardiol; 2010 Apr; 55(15):1611-8. PubMed ID: 20378080
[TBL] [Abstract][Full Text] [Related]
19. Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes.
Chambergo-Michilot D; Alur A; Kulkarni S; Agarwala A
Vasc Health Risk Manag; 2022; 18():73-80. PubMed ID: 35221690
[TBL] [Abstract][Full Text] [Related]
20. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
Morse MA
Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
